Nuvectis (NVCT) Net earnings per share growth forecast for next year

Corporate company logo of Nuvectis Pharma, Inc. (NVCT)

Nuvectis Pharma, Inc. (NVCT) operates in a high-risk zone where the competition with global behemoths over clinical trial timelines determines success. Patents for kinase inhibitors and strict FDA oversight serve as defensive assets. The implementation of laboratory robotics accelerates molecule discovery. This chart of EPS growth prospects for the next fiscal year shows that the figure is 16.60.

Nuvectis (NVCT): Net earnings per share growth forecast for next year from 07/04/2022 to 11/16/2026

Summary analytical data breakdowns for Nuvectis (NVCT)

- share price and consensus valuation forecast:
Fundamental company analysis:Nuvectis Pharma, Inc.
Finished products of Nuvectis Pharma Inc.

Analyzing the projected EPS growth for the next fiscal year, we assess the status of Nuvectis Pharma, Inc. (NVCT) as a virtual biopharmaceutical player. This indicator reflects the consensus forecast for earnings per share changes, signaling an upcoming revaluation of the business value. The metric's trend is sensitive to costs associated with third-party contractors (CRO/CMO), which are critical for conducting trials. The stability of the curve confirms the resilience of patents against operational outsourcing risks.

Competitor analysis for Nuvectis Pharma, Inc.

INCY (incyte.com) - Earnings growth forecast for next year|Expected net earnings per share growth next year hutch-med.com HCM|Net earnings per share growth forecast for next year Nuvation Corp (NUVB)|DAWN - Expected net earnings per share growth next year|Net earnings per share growth forecast for next year Monopar Pharma MNPR|Inhibrx Corp - Net earnings per share growth forecast for next year|IMAB - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year Fennec Pharmaceuticals|HRTX: Earnings growth forecast for next year|Net earnings per one share growth forecast for next year Coherus CHRS|Expected earnings per share growth for next year CRBP|Expected net earnings per share growth next year Cardiff Oncology CRDF|Expected earnings per share growth for next year BYSI (BeyondSpring Inc.)|BCAB (BioAtla Corp) - Expected earnings per share trend next year|Lixte Biotechnology - Expected earnings per share growth for next year|Projected earnings per share increase next year CTXR (Citius Pharma)|Cellectar - Earnings growth forecast for next year|Expected earnings per share trend next year BLRX (BioLineRx Corp)|CANF: Earnings growth forecast for next year|Expected net earnings per share growth next year Aprea (APRE)|Net earnings per share growth forecast for next year kaziatherapeutics.com|SLXN: Expected earnings per share trend next year|Earnings growth forecast for next year NCNA|Earnings growth forecast for next year Chimerix Inc (CMRX)|Net earnings per share growth forecast for next year Cyclacel Pharmaceuticals Inc. CYCC|GTHX (g1therapeutics.com) - Net earnings per share change forecast for next year|KRON: Expected earnings per share growth for next year|Expected net earnings per share growth next year Kintara Therapeutics Inc|oncternal.com (ONCT) - Net earnings per share growth forecast for next year|Net earnings per share change forecast for next year PRTG (Portage Biotech Corp)